Addition of low dose acetazolamide as an adjunct in patients undergoing high dose methotrexate is safe and beneficial
Authors:
- 12 August 2019
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 50 (3) , 357-362
Abstract
Background: High‐dose methotrexate (HDMTx) is utilised in central nervous system lymphoma and acute lymphoblastic leukaemia due to its ability to penetrate the blood–brain barrier. Despite its efficacy, nephrotoxicity is a potentially serious toxicity that could also exacerbate other methotrexate‐related toxicities and compromise dose intensity. Acetazolamide (AZL) is a carbonic anhydrase inhibitor that causes an increase in bicarbonate excretion and consequently urine alkalinisation. Following occurrences of HDMTx‐induced acute kidney injury (AKI) due to inadequate urine alkalinisation at our institution, routine AZL was administered to appropriate patients from 2010 onwards.Aims: To analyse the addition of AZL to routine renoprotective measures, given that inadequate urinary alkalinisation is the major risk factor for methotrexate crystal precipitation and prolonged excretion. In addition, since fluid overload is a common consequence of HDMTx treatment, the effect of AZL on fluid balance was also examined.Methods: This is a retrospective, single‐centred cohort study examining the mitigation of HDMTx‐induced toxicities by AZL in 92 patients over a 6‐year period.Results: AZL showed a strong trend of preventing either AKI (as per CTCAE version 4.03) or delayed methotrexate elimination (>5 days), especially in males. Furthermore, AZL also resulted in reduced weight gain and fewer episodes of urinary pH <7.0.Conclusion: AZL appeared to diminish the incidence of HDMTx‐induced toxicities, including reducing oedema‐related weight gain. With mild, preventable hypokalaemia as the only noteworthy toxicity, AZL could be considered as an adjunct to HDMTx patient care.Keywords
This publication has 36 references indexed in Scilit:
- Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)Journal of Clinical Oncology, 2013
- Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in HaematologyBritish Journal of Haematology, 2013
- Diagnosis and treatment of primary CNS lymphomaNature Reviews Neurology, 2013
- Prevention of CNS relapse in diffuse large B-cell lymphomaThe Lancet Oncology, 2011
- Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexateBritish Journal of Clinical Pharmacology, 2011
- High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphomaNeuro-Oncology, 2010
- Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trialBritish Journal of Cancer, 2010
- High-dose methotrexate for elderly patients with primary CNS lymphomaNeuro-Oncology, 2009
- Primary central nervous system lymphoma – Biological aspects and controversies in managementEuropean Journal of Cancer, 2007
- Determinants of the elimination of methotrexate and 7‐hydroxy‐methotrexate following high‐dose infusional therapy to cancer patientsBritish Journal of Clinical Pharmacology, 2005